approved in 2017 for relapsing and primary progressive forms of MS, is seen as one of the most successful drug launches in pharma history, generating sales of $3.79 billion in 2019. Kesimpta, a ...

Nearly nine out of ten patients treated with Kesimpta saw no evidence of disease activity in their second year of treatment with the drug. Relapsing and remitting forms of MS account for around 85 ...